ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan's Shionogi seeks approval for COVID pill in South Korea

Drugmaker pursues first overseas authorization for Xocova treatment

Japanese drugmaker Shionogi looks to manufacture and sell its COVID antiviral pill Xocova in overseas markets. (Photo by Yo Inoue)

OSAKA -- Japanese drugmaker Shionogi said Wednesday that its COVID-19 pill has been submitted for approval in South Korea, the first official application for the treatment overseas.

Shionogi is conducting clinical trials of its antiviral tablet Xocova in South Korea and Vietnam. Ildong Pharmaceutical, Shionogi's Seoul-based partner, submitted the application for Xocova on behalf of the Japanese company. The drug, whose generic name is ensitrelvir, can be used to treat patients with mild symptoms.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more